select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Candidiasis-Pipeline Review, H1 2017

Candidiasis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9085IDB
  • |
  • Pages: 147
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Candidiasis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis-Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Candidiasis-Overview 8

Candidiasis-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Candidiasis-Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Candidiasis-Companies Involved in Therapeutics Development 27

Amplyx Pharmaceuticals Inc 27

Bakker Medical Srl 27

Biomar Microbial Technologies 28

Biosergen AS 28

Cidara Therapeutics Inc 29

CSA Biotechnologies LLC 29

Daewoong Pharmaceutical Co Ltd 30

Dermala Inc 30

General Biologicals Corp 31

Grupo Ferrer Internacional SA 31

Hsiri Therapeutics LLC 32

iCo Therapeutics Inc. 32

ImmunoClin Corp 33

Matinas BioPharma Holdings Inc 33

Nanomerics Ltd 34

NovaDigm Therapeutics Inc 34

Novartis AG 35

Onxeo SA 35

Scynexis Inc 36

Sealife PHARMA GMBH 36

Viamet Pharmaceuticals Inc 37

Visterra Inc 37

Wellstat Vaccines LLC 38

Candidiasis-Drug Profiles 39

(clotrimazole + diclofenac sodium)-Drug Profile 39

61894700-Drug Profile 40

AC-17-Drug Profile 41

amphotericin B-Drug Profile 42

amphotericin B-Drug Profile 44

amphotericin B-Drug Profile 48

Amphotericin B sodium-Drug Profile 49

Antibody to Target Ece1 for Candidiasis-Drug Profile 51

APX-001-Drug Profile 52

APX-001A-Drug Profile 54

arasertaconazole-Drug Profile 55

B-4010-Drug Profile 56

BL-5923-Drug Profile 57

BSG-005-Drug Profile 58

candidiasis vaccine-Drug Profile 59

CD-101-Drug Profile 60

Cellullar Immunotherapy for Viral Infections and Fungal Infections-Drug Profile 64

CSA-13-Drug Profile 65

Drug for Candidiasis-Drug Profile 67

DWP-06081-Drug Profile 68

Forazoline A-Drug Profile 69

iCo-010-Drug Profile 70

interleukin-22-Drug Profile 71

JSM-11-Drug Profile 72

KSL-W-Drug Profile 73

miconazole nitrate-Drug Profile 74

Monoclonal Antibodies for Candidiasis-Drug Profile 76

Monoclonal Antibody for Candidiasis-Drug Profile 77

Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections-Drug Profile 78

mutanobactin A-Drug Profile 79

NDV-3-Drug Profile 80

NDV-3A-Drug Profile 82

NP-339-Drug Profile 84

obliquumol-Drug Profile 85

Occidiofungin-Drug Profile 86

P-113Du-Drug Profile 87

P-113Tri-Drug Profile 88

PAC-113-Drug Profile 89

Polymers for Clostridium difficile Infections and Candidiasis-Drug Profile 91

Prof-002-Drug Profile 92

Recombinant Enzyme for Candidiasis-Drug Profile 93

Recombinant Peptides for Oropharyngeal Candidiasis-Drug Profile 94

SCY-078-Drug Profile 95

SLP-0901-Drug Profile 100

SLP-0904-Drug Profile 101

Small Molecule for Bacterial Vaginosis and Candidiasis-Drug Profile 102

Small Molecule for Fungal Infections-Drug Profile 103

Small Molecules for Aspergillosis and Candidiasis-Drug Profile 104

Small Molecules for Candidiasis-Drug Profile 105

Small Molecules for Candidiasis-Drug Profile 106

Small Molecules for Candidiasis-Drug Profile 107

Small Molecules for Fungal Infections-Drug Profile 108

Small Molecules for Fungal Infections-Drug Profile 109

Small Molecules for Systemic Candidiasis-Drug Profile 110

Synthetic Peptide to Inhibit CBL-B for Candidiasis-Drug Profile 111

Synthetic Peptides for Candidiasis-Drug Profile 112

Synthetic Peptides for Infections Diseases and Oncology-Drug Profile 113

TOL-463-Drug Profile 114

Vaccine to Target Ece1 for Candidiasis-Drug Profile 115

Vaccine to Target Glucosylceramide for Fungal Infections-Drug Profile 116

VIS-FNG-Drug Profile 117

VT-1129-Drug Profile 118

VT-1161-Drug Profile 120

Candidiasis-Dormant Projects 126

Candidiasis-Discontinued Products 129

Candidiasis-Product Development Milestones 130

Featured News & Press Releases 130

Appendix 141

Methodology 141

Coverage 141

Secondary Research 141

Primary Research 141

Expert Panel Validation 141

Contact Us 141

Disclaimer 142

List of Figures

Number of Products under Development for Candidiasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Candidiasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Candidiasis-Pipeline by Amplyx Pharmaceuticals Inc, H1 2017

Candidiasis-Pipeline by Bakker Medical Srl, H1 2017

Candidiasis-Pipeline by Biomar Microbial Technologies, H1 2017

Candidiasis-Pipeline by Biosergen AS, H1 2017

Candidiasis-Pipeline by Cidara Therapeutics Inc, H1 2017

Candidiasis-Pipeline by CSA Biotechnologies LLC, H1 2017

Candidiasis-Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Candidiasis-Pipeline by Dermala Inc, H1 2017

Candidiasis-Pipeline by General Biologicals Corp, H1 2017

Candidiasis-Pipeline by Grupo Ferrer Internacional SA, H1 2017

Candidiasis-Pipeline by Hsiri Therapeutics LLC, H1 2017

Candidiasis-Pipeline by iCo Therapeutics Inc., H1 2017

Candidiasis-Pipeline by ImmunoClin Corp, H1 2017

Candidiasis-Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Candidiasis-Pipeline by Nanomerics Ltd, H1 2017

Candidiasis-Pipeline by NovaDigm Therapeutics Inc, H1 2017

Candidiasis-Pipeline by Novartis AG, H1 2017

Candidiasis-Pipeline by Onxeo SA, H1 2017

Candidiasis-Pipeline by Scynexis Inc, H1 2017

Candidiasis-Pipeline by Sealife PHARMA GMBH, H1 2017

Candidiasis-Pipeline by Viamet Pharmaceuticals Inc, H1 2017

Candidiasis-Pipeline by Visterra Inc, H1 2017

Candidiasis-Pipeline by Wellstat Vaccines LLC, H1 2017

Candidiasis-Dormant Projects, H1 2017

Candidiasis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Candidiasis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Candidiasis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amplyx Pharmaceuticals Inc, Bakker Medical Srl, Biomar Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, CSA Biotechnologies LLC, Daewoong Pharmaceutical Co Ltd, Dermala Inc, General Biologicals Corp, Grupo Ferrer Internacional SA, Hsiri Therapeutics LLC, iCo Therapeutics Inc., ImmunoClin Corp, Matinas BioPharma Holdings Inc, Nanomerics Ltd, NovaDigm Therapeutics Inc, Novartis AG, Onxeo SA, Scynexis Inc, Sealife PHARMA GMBH, Viamet Pharmaceuticals Inc, Visterra Inc, Wellstat Vaccines LLC

Candidiasis Therapeutic Products under Development, Key Players in Candidiasis Therapeutics, Candidiasis Pipeline Overview, Candidiasis Pipeline, Candidiasis Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com